Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Road Walker who wrote (459257)	2/25/2009 11:14:43 AM
From: i-node	1 Recommendation Respond to of 1573426

But only 40% of the top 10. How do you think they got to be top 10? Well, I guess if you want to draw an arbitrary distinction like that, even though it makes no sense to do so, you can ask the question. However, it is a natural product of globalization of business that you would have some foreign ownership in drug companies. FOR EXAMPLE, Glaxo Smith Kline, considered the 4th biggest and technically based in UK, was an outgrowth of the acquisition of Smith Kline Beckman, and the United States comprises its single largest market. That is to say, that even though it is not a "US Drug Company", its biggest market is the United States and the substantial part of its operations are here, as well. Pretty much all these big drug companies with "homes" in other countries do a big business, if not the BIGGEST business, in the United States. For example, Novartis has massive research activities in the United States in every specialty area. It is almost essential, if you're going to target the American drug market, to do a substantial portion, if not all, of the research here.